TrialRMD open2025

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Patrick G Gavin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.